Skip to main content
LIFECOME BIOCHEMISTRY CO., LTD. logo

LIFECOME BIOCHEMISTRY CO., LTD. — Investor Relations & Filings

Ticker · 002868 ISIN · CNE100002QH2 LEI · 65560089EP03NANEN790 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,742 across all filing types
Latest filing 2025-06-27 Audit Report / Informat…
Country CN China
Listing Shenzhen Stock Exchange 002868

About LIFECOME BIOCHEMISTRY CO., LTD.

https://www.pclifecome.com

Lifecome Biochemistry Co., Ltd. focuses on the research, development, and large-scale production of fermentation-based veterinary pharmaceuticals and feed additives. The company’s core product portfolio includes Bacitracin Zinc, Bacitracin Methylene Disalicylate (BMD), and Colistin Sulfate, available in both active pharmaceutical ingredient (API) and premix forms. These biochemical products are primarily utilized in the livestock and poultry sectors to manage enteric health and improve feed efficiency. The organization operates advanced fermentation and purification facilities, maintaining compliance with international Good Manufacturing Practices (GMP) and various global regulatory standards. By leveraging specialized biotechnological processes, the company provides high-purity solutions aimed at enhancing animal nutrition and disease prevention across international markets.

Recent filings

Filing Released Lang Actions
浙商证券股份有限公司关于公司本次重大资产重组前发生业绩异常或存在拟置出资产情形的相关事项之专项核查意见
Audit Report / Information Classification · 95% confidence The document is a detailed independent financial advisor's special investigation opinion related to a major asset restructuring involving the sale of subsidiaries by a listed company, including extensive financial data, audit opinions, compliance checks, and asset valuation reports. It references multiple years of audited financial statements (2022-2024), audit reports with unqualified opinions, and compliance with accounting standards. The document also discusses regulatory approvals, shareholder commitments, and internal controls. The presence of detailed financial data, audit opinions, and compliance analysis indicates this is a standalone audit report or special investigation report related to a transaction, not a full annual report or earnings release. It is not a brief announcement or a certification letter but a substantive report. Therefore, the document fits best under the category Audit Report / Information (AR). FY 2024
2025-06-27 Chinese
第五届监事会第十三次（临时）会议决议
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement of resolutions passed at the 13th (extraordinary) meeting of the 5th Supervisory Board of LvKang Biochemical Co., Ltd. The content focuses on approval and discussion of a major asset restructuring transaction, including asset sale details, pricing, legal compliance, and related party transactions. It references compliance with laws and regulations related to major asset restructuring and mentions that the proposals still require shareholder meeting approval. The document is not a full financial report but a formal announcement of board-level decisions regarding a significant transaction. This fits the category of a Capital/Financing Update (CAP) because it details a major asset sale and restructuring transaction, including financing and capital structure implications. It is not an Annual Report, Audit Report, or Merger & Acquisition filing per se, but a corporate announcement of a major asset restructuring transaction. The document length (8860 characters) and detailed content support this classification with high confidence.
2025-06-27 Chinese
浙商证券股份有限公司关于本次关联交易的核查意见
Audit Report / Information Classification · 95% confidence The document is a detailed independent financial advisor's verification opinion on a related-party transaction involving a major asset sale by a listed company. It references regulatory frameworks such as the China Securities Regulatory Commission's rules on major asset restructurings and mergers and acquisitions. The document includes extensive background, transaction details, valuation reports, decision-making procedures, and independent financial advisor opinions. It is not a full annual or interim financial report, nor is it a simple announcement or certification. The content focuses on the review and opinion on a major asset restructuring and related-party transaction, which aligns with the category of Audit Report / Information (AR), as it involves an independent financial advisor's audit and verification opinion on a significant transaction, including valuation and compliance with regulatory requirements. The document length (8487 characters) and detailed content support this classification rather than a brief announcement or a full annual report. Q2 2025
2025-06-27 Chinese
绿康（玉山）胶膜材料有限公司评估报告（银信评报字（2025）第C00091号）
Audit Report / Information Classification · 95% confidence The document is titled as an "资产评估报告" (Asset Evaluation Report) and is prepared according to Chinese asset evaluation standards. It is a detailed report assessing the market value of the entire equity of a subsidiary company (绿康（玉山）胶膜材料有限公司) as of December 31, 2024. The report includes extensive financial data, asset and liability details, valuation methods, and conclusions. It is commissioned by the parent company (绿康生化股份有限公司) for the purpose of an asset disposal transaction. The document is lengthy (15,000 characters) and contains substantive financial and valuation information, not merely an announcement or certification. This fits the definition of an Audit Report / Information (AR) as it is a standalone asset valuation report related to a specific transaction, distinct from a full Annual Report or Interim Report. Therefore, the appropriate classification is AR with high confidence. FY 2024
2025-06-27 Chinese
绿康生化重大资产重组前发生业绩异常或本次重组存在拟置出资产情形的专项核查意见
Legal Proceedings Report Classification · 95% confidence The document is a detailed legal opinion issued by a law firm regarding a major asset restructuring of a listed company, including a special investigation on abnormal performance before the restructuring and the existence of proposed asset disposal. It references compliance with Chinese securities laws and regulations, and includes verification of the company's past three years' operational compliance, absence of illegal fund occupation, guarantees, penalties, and investigations. The document is a legal advisory report related to a significant corporate restructuring event, not a financial report, earnings release, or management discussion. It is not a proxy, voting result, or announcement of a report publication. The document is a specialized legal opinion on a major asset restructuring, which fits best under the category of Legal Proceedings Report (LTR) as it deals with legal compliance and regulatory matters related to the restructuring.
2025-06-27 Chinese
绿康生化关于本次重大资产出售暨关联交易的一般风险提示公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by the company regarding a major asset sale and related party transaction. It references previous announcements and board meeting approvals but does not contain detailed financial statements or comprehensive report data. The document is relatively short (712 characters) and serves as a risk warning and update on the transaction progress. It is not a full report like an Annual Report or Interim Report, nor is it a detailed investor presentation or earnings release. It fits best as a Regulatory Filing (RNS) because it is a general regulatory announcement about a significant corporate transaction and related risks without detailed financial data or formal report structure.
2025-06-27 Chinese

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.